EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia

Qiu-Sha Huang, Hai-Xia Fu iD, Chen-Cong Wang, Xiao-Lu Zhu iD, Yun He, Jin Wu, Qi Chen, Peng Zhao, Zhuo-Yu An iD, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang iD

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27718 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Qiu-Sha Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. Hauptthemen laut MEDLINE: Pyrimidines, Agammaglobulinaemia Tyrosine Kinase, Purpura, Thrombocytopenic, Idiopathic, Pyrazoles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund, Key Program of National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is characterized by impaired platelet production and increased platelet destruction. Zanubrutinib is a highly selective next‐generation Bruton tyrosine kinase (BTK) inhibitor that may reduce autoantibody production and reduce macrophage Fcγ receptor‐mediated platelet destruction. In this single‐arm, phase II study, we aimed to assess the efficacy and safety of zanubrutinib in corticosteroid‐resistant or relapsed ITP. All patients received 80 mg zanubrutinib once daily for 6 weeks followed by a 20‐week safety follow‐up period. The primary endpoint was overall response (OR), defined as at least two consecutive platelet counts of at least 30 × 10 9 /L, at least a 2‐fold increase in the baseline count, the absence of bleeding, and no need for rescue therapy at 4 weeks. The trial was registered with ClinicalTrials.gov , number NCT05279872. Between January 1, 2022 and October 30, 2022, 20 patients were enrolled. The median platelet count was 19 (10–25) × 10 9 /L at the time of enrollment. Participants had received a median of 4 (3–6) different therapies for ITP. Eleven (55%, 95% CI: 31.5%–76.9%) patients achieved an OR to the intervention. Two (10%) patients achieved a complete response. At the 6‐month follow‐up, a sustained response was achieved in seven (35.0%, 95% CI: 15.4%–59.2%) patients. There were no grade 4 or worse adverse events or treatment‐related deaths. The most common adverse events were upper respiratory tract infection (in 25% of the patients). Zanubrutinib showed an encouraging response rate and tolerability, supporting its therapeutic potential for the treatment of ITP. Trial Registration: ClinicalTrials.gov identifier: NCT05279872.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesAgammaglobulinaemia Tyrosine KinasePurpura, Thrombocytopenic, IdiopathicPyrazolesPiperidinesProtein Kinase InhibitorsHumansFemaleMaleMiddle AgedAdultAgedPlatelet CountTreatment OutcomeTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Bruton's tyrosine kinase inhibitorclinical trialsimmune thrombocytopenia

Substanzen

zanubrutinibPyrimidinesAgammaglobulinaemia Tyrosine KinasePyrazolesPiperidinesProtein Kinase InhibitorsBTK protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Collaborative Innovation Center of Hematology, Peking University, Beijing, China.

ORCID-Profile: Hai-Xia Fu, Xiao-Lu Zhu, Zhuo-Yu An, Xiao-Hui Zhang

Förderung

  • Capital Health Research and Development of Special Fund
  • Key Program of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Key Programme

Zitieren

APA

Huang, Q. S., Fu, H. X., Wang, C. C., Zhu, X. L., He, Y., Wu, J., Chen, Q., Zhao, P., An, Z. Y., Liu, K. Y., Huang, X. J., & Zhang, X. H. (2025). Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia. American Journal of Hematology. https://doi.org/10.1002/ajh.27718

Vancouver

Huang QS, Fu HX, Wang CC, Zhu XL, He Y, Wu J, et al. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia. American Journal of Hematology. 2025. doi:10.1002/ajh.27718

BibTeX
@article{Huang2025,
  author = {Huang, Qiu-Sha and Fu, Hai-Xia and Wang, Chen-Cong and Zhu, Xiao-Lu and He, Yun and Wu, Jin and Chen, Qi and Zhao, Peng and An, Zhuo-Yu and Liu, Kai-Yan and Huang, Xiao-Jun and Zhang, Xiao-Hui},
  title = {Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27718}
}
Kostenlos starten →